Pacer Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

Pacer Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-614	Closed	-$20K	–	1513
2021 Q1	$20K	Buy	+614	New	+$24.2K	﹤0.01%	1505

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Pacer Advisors's PMVP Position: Q2 2021 in Review

Pacer Advisors sold out of PMV Pharmaceuticals (PMVP) in Q2 2021, closing a stake of 614 shares — an estimated $20K sold.

Pacer Advisors first reported a position in PMVP in Q1 2021 and held it in 1 quarter. The position peaked at $20K in Q1 2021. 85 funds tracked by Wall St. Rank hold PMVP as of Q2 2021.

Pacer Advisors reported no remaining PMV Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Pacer Advisors sold 614 PMV Pharmaceuticals shares in Q2 2021, an estimated $20K.
Pacer Advisors first reported a position in PMV Pharmaceuticals in Q1 2021 and held it in 1 quarter.
Pacer Advisors's PMV Pharmaceuticals position peaked at $20K in Q1 2021.
85 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.